Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17163357 | 1.00 | CYP3A4 (0.53) | CYP3A4HSD17B10SIGMAR1GAAOPRL1 | |
| SCHEMBL13201397 | 1.00 | CYP3A4 (0.53) | CYP3A4HSD17B10SIGMAR1GAAOPRL1 | |
| Hydrochloric Acid SCHEMBL1036101 | 0.98 | CYP3A4 (0.51) | CYP3A4HSD17B10SIGMAR1GAAOPRL1 | |
| SCHEMBL7500958 | 0.90 | CYP2D6 (0.56) | CYP3A4HSD17B10SIGMAR1GAATSHR | |
| SCHEMBL1994180 | 0.89 | SIGMAR1 (0.61) | CYP3A4HSD17B10SIGMAR1OPRL1TSHR | |
| Ammonia Solution, Strong SCHEMBL27704870 | 0.88 | CYP3A4 (0.59) | CYP3A4HSD17B10SIGMAR1OPRL1TSHR | |
| Hydrochloric Acid SCHEMBL15608841 | 0.88 | CYP3A4 (0.59) | CYP3A4HSD17B10SIGMAR1OPRL1TSHR | |
| SCHEMBL867675 | 0.85 | GAA (0.62) | CYP3A4HSD17B10SIGMAR1GAAOPRL1 | |
| SCHEMBL4817148 | 0.82 | CYP3A4 (0.56) | CYP3A4HSD17B10SIGMAR1GAAOPRL1 | |
| SCHEMBL2262610 | 0.82 | CYP3A4 (0.56) | CYP3A4HSD17B10SIGMAR1GAAOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| CN-109526219-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-7576121-B2 | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV | PHENOMIX CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| EP-2010488-A2 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117559-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117559-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-0787726-B1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-5817669-A | A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0787726-A1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | CYP3A4 505/4885HSD17B10 3080/4885SIGMAR1 3293/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | CYP3A4 3635/4885HSD17B10 3541/4885SIGMAR1 4236/4885 |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | CYP3A4 505/4885HSD17B10 3080/4885SIGMAR1 3293/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | CYP3A4 505/4885HSD17B10 3080/4885SIGMAR1 3293/4885 |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | CYP3A4 442/4885HSD17B10 2899/4885SIGMAR1 3544/4885 |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | CYP3A4 3150/4885HSD17B10 2570/4885SIGMAR1 268/4885 |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | CYP3A4 505/4885HSD17B10 3080/4885SIGMAR1 3293/4885 |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | CYP3A4 442/4885HSD17B10 2899/4885SIGMAR1 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.